Oppenheimer reiterates Veru stock rating ahead of obesity trial data
Oppenheimer maintained an Outperform rating and $24.00 price target for Veru (VERU), citing potential obesity treatment trial results. The stock is down 11% in a week. Veru reported a smaller-than-expected Q3 loss and has sufficient cash for operations. Phase 2b PLATEAU study interim results are expected in Q1 2027.
How this was made
The 30-second read
Why it matters
The analyst's reiteration could attract short‑term buying interest, but the real catalyst remains the upcoming trial readout.
Market read
The article offers a modest rating update without new data; relevance for traders is limited.
What to watch
Potential competition from other GLP‑1 adjuncts and the company's cash runway constraints.
Background
Veru reported a smaller Q3 loss and increased cash, while its Phase 2b PLATEAU study is fully enrolled.
Ticker impact
Oppenheimer reiterated an Outperform rating and $24 price target for Veru ahead of its Phase 2b obesity trial readout.
potential upward pressure as market prices in the upgraded rating and upcoming data expectations
The reiteration adds a higher target but no new data; price move depends on trial outcome.
Market effects
Limited impact on the broader biotech sector; only investors focused on obesity therapeutics may react.
US market only; no regional spillover.
Low; the story is company‑specific.
Counterpoint
The upgrade may be premature without data; the stock could face downside if the trial fails.
Key entities
- companyVeru, Inc.
Biotech firm developing obesity‑adjunct therapy.
- analystOppenheimer
Equity research firm providing the rating.

